Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial-Reference-Cited by-同舟云学术

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Published:2023-01-12 Issue:3 Volume:37 Page:699-701
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Zander Thilo^ORCID,Pabst Thomas^ORCID,Schär Sämi^ORCID,Aebi Stefan,Mey Ulrich,Novak Urban,Lerch Erika,Rhyner Agocs Gaëlle,Goede Jeroen,Maniecka Zuzanna,Hayoz Stefanie^ORCID,Rüfer Axel,Renner Christoph,Driessen Christoph

Funder

Krebsliga Schweiz

Swiss Group for Clinical Cancer Research (SAKK) LOA IV funds (managed by curafutura, santésuisse, pharma suisse) Swiss State Secreteriat of Education, Research and Innovation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01809-z.pdf

Reference15 articles.

1. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.

2. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497–503.

3. Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, et al. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis. Eur J Haematol. 2017;99:199–206.

4. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781–94.

5. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (Lond, Engl). 2019;394:2096–107.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy;Annals of Oncology;2023-08